239 related articles for article (PubMed ID: 32425926)
21. A novel α-fetoprotein-derived helper T-lymphocyte epitope with strong immunogenicity in patients with hepatocellular carcinoma.
Tamai T; Mizukoshi E; Kumagai M; Terashima T; Iida N; Kitahara M; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Honda M; Fushimi K; Kaneko S
Sci Rep; 2020 Mar; 10(1):4021. PubMed ID: 32132566
[TBL] [Abstract][Full Text] [Related]
22. Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine.
Bei R; Mizejewski GJ
Curr Mol Med; 2011 Oct; 11(7):564-81. PubMed ID: 21707514
[TBL] [Abstract][Full Text] [Related]
23. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
24. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma.
Ritter M; Ali MY; Grimm CF; Weth R; Mohr L; Bocher WO; Endrulat K; Wedemeyer H; Blum HE; Geissler M
J Hepatol; 2004 Dec; 41(6):999-1007. PubMed ID: 15582134
[TBL] [Abstract][Full Text] [Related]
25. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
[TBL] [Abstract][Full Text] [Related]
26. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
[TBL] [Abstract][Full Text] [Related]
27. Glycoprotein 96 and α-fetoprotein cross-linking complexes elicited specific antitumor immunity.
Wang XP; Wang QX; Lin HP; Wang YL; Yang Y
Cancer Biother Radiopharm; 2013 Jun; 28(5):406-14. PubMed ID: 23484810
[TBL] [Abstract][Full Text] [Related]
28. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.
Butterfield LH; Ribas A; Dissette VB; Lee Y; Yang JQ; De la Rocha P; Duran SD; Hernandez J; Seja E; Potter DM; McBride WH; Finn R; Glaspy JA; Economou JS
Clin Cancer Res; 2006 May; 12(9):2817-25. PubMed ID: 16675576
[TBL] [Abstract][Full Text] [Related]
29. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.
Butterfield LH; Meng WS; Koh A; Vollmer CM; Ribas A; Dissette VB; Faull K; Glaspy JA; McBride WH; Economou JS
J Immunol; 2001 Apr; 166(8):5300-8. PubMed ID: 11290817
[TBL] [Abstract][Full Text] [Related]
30. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma.
Liu Q; Tian Y; Li Y; Zhang W; Cai W; Liu Y; Ren Y; Liang Z; Zhou P; Zhang Y; Bao Y; Li Y
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323464
[TBL] [Abstract][Full Text] [Related]
31. Lack of ex vivo peripheral and intrahepatic α-fetoprotein-specific CD4+ responses in hepatocellular carcinoma.
Witkowski M; Spangenberg HC; Neumann-Haefelin C; Büttner N; Breous E; Kersting N; Drognitz O; Hopt UT; Blum HE; Semmo N; Thimme R
Int J Cancer; 2011 Nov; 129(9):2171-82. PubMed ID: 21170957
[TBL] [Abstract][Full Text] [Related]
32. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
[TBL] [Abstract][Full Text] [Related]
33. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination.
Meng WS; Butterfield LH; Ribas A; Dissette VB; Heller JB; Miranda GA; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2001 Dec; 61(24):8782-6. PubMed ID: 11751399
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice.
Zhang W; Liu J; Wu Y; Xiao F; Wang Y; Wang R; Yang H; Wang G; Yang J; Deng H; Li J; Wen Y; Wei Y
Biochem Biophys Res Commun; 2008 Nov; 376(1):10-4. PubMed ID: 18725206
[TBL] [Abstract][Full Text] [Related]
35. Potentiality of α-fetoprotein (AFP) and soluble intercellular adhesion molecule-1 (sICAM-1) in prognosis prediction and immunotherapy response for patients with hepatocellular carcinoma.
Cao W; Chen Y; Han W; Yuan J; Xie W; Liu K; Qiu Y; Wang X; Li X
Bioengineered; 2021 Dec; 12(2):9435-9451. PubMed ID: 34696675
[TBL] [Abstract][Full Text] [Related]
36. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
37. [Effect of PLGA nanoparticles conjugated with anti-OX40/anti-AFP mAbs on cytotoxicity of CTL cells against hepatocellular carcinoma].
Chen M; Ouyang H; Zhou S; Li J; Ye Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Apr; 30(4):337-41. PubMed ID: 24721396
[TBL] [Abstract][Full Text] [Related]
38. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
[TBL] [Abstract][Full Text] [Related]
39. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
40. A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days.
Kobayashi E; Mizukoshi E; Kishi H; Ozawa T; Hamana H; Nagai T; Nakagawa H; Jin A; Kaneko S; Muraguchi A
Nat Med; 2013 Nov; 19(11):1542-6. PubMed ID: 24121927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
